Rinaina,
The prediction aid that is most commonly accepted is Adjuvant!, and so far it does not provide the ability to specify HER2 status. It is regularly updated and still those who put together are not yet willing to give projections specific to HER2's. Oncs may have a sort of general impression from their own practice or from various clinical trials but there isn't any definite clear info for us about that.
If they can't say, then I think it is pretty bogus on their part to continue year after year to exclude anyone who is HER2+++ from getting traztuzumab no matter how far out from original treatment.
Perhaps they feel cancer patients aren't smart enough to figure that out.
BOO HISS.
AlaskaAngel
|